Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
26 participants
OBSERVATIONAL
2016-03-31
2018-03-23
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Neoadjuvant FOLFIRINOX in the Treatment of Locally Advanced Gastric Cancer
NCT03825861
Phase III Trial of DP Followed by FOLFIRI or the Reverse Sequence in Unresectable Gastric Cancer
NCT00313872
Metastatic Gastric Cancer FFCD 03-07
NCT00374036
FOLFIRI Versus Docetaxel and Cisplatin as a Second-line Chemotherapy After Failure of First-line Chemotherapy in Advanced Gastric Cancer
NCT03067792
Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma
NCT03959293
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Eastern Cooperative Oncology Group performance status ≤2 (ECOG PS)
* aged \> 18 years
* neutrophil count ≥1500/μl
* platelet count ≥100 000/μl),
* renal (serum creatinine ≤1.5 mg/dl)
* liver (serum bilirubin ≤2 mg/dL) functions
* normal cardiac function,
* absence of second primary tumor other than non-melanoma skin cancer
* no concurrent uncontrolled medical illness.
Exclusion Criteria
* No prior treatment with ramucirumab
* operable metastatic disease were excluded from the study
* severe cardiac dysfunction, congestive heart failure or a recent myocardial infarction
* uncontrolled sites of infection.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
IRCCS Cancer Referral Center of Basilicata
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Giandomenico Roviello
MS, PhD
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRCCS-CROB
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.